GlassScriptPhysician profile
Loren Carlson
NPI 1902829419
$16,197.28
in general payments reported to CMS, 2019-2025
57 companies · $2,167 in 2025
The $2,167 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,953 · 2020: $1,737 · 2021: $3,366 · 2022: $2,392 · 2023: $1,481 · 2024: $3,101 · 2025: $2,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,722 · Education: $26.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,721.57 |
| Education | $26.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,578.94 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $2,201.56 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $1,889.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,047.63 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $727.93 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Esperion Therapeutics, INC. | $687.27 | 2020-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $622.99 | 2019-2025 | Jardiance, Synjardy |
| Pfizer INC. | $511.88 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $490.36 | 2021-2024 | |
| Abbvie INC. | $326.26 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $285.33 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $280.70 | 2019-2025 | Leqvio |
| Biohaven Pharmaceuticals, INC. | $256.87 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $248.98 | 2019-2024 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $235.99 | 2022 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loren Carlson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.